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OBJECTIVES: Primary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in
other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin
has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to
evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and
groin).
METHODS: This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary
focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before
beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to
measure their improvement at each site of excessive sweating after six weeks and at the last consult.
RESULTS: The median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites
were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry
mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth.
Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one:
palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main
sites of sweating.
CONCLUSION: After six weeks, more than 80% of the patients presented with improvements in their overall
quality of life and at the most important site of sweating. Side effects were common (80% reported at least one
side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating
bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects.
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& INTRODUCTION
Primary hyperhidrosis is a common disease with an
incidence of up to 2.8% in the United States (1). Excessive
sudoresis negatively impacts quality of life (QOL) (2), and
its resolution is linked to QOL improvement (3,4).
The most common sites of primary hyperhidrosis are the
axillae, palms of the hands, soles of the feet and cranio-facial
region; the vast majority of scientific papers describing
primary hyperhidrosis have focused on these regions.
Excessive focal sweating elsewhere (e.g., the thorax, abdo-
men, back or groin) usually occurs after surgical sympathect-
omy (as compensatory hyperhidrosis); this condition may be
reduced with the use of certain techniques (5), but it is still one
of the most common causes of sweating in these areas.
A fraction of patients have a primary complaint of
hyperhidrosis at less common sites (e.g., the back and
groin), but they do not fulfill the criteria for compensatory
hyperhidrosis (as they have never undergone an operation),
secondary hyperhidrosis (as no clinical/pharmacological
condition has been diagnosed) or generalized hyperhidrosis
(as they do not sweat on the majority of their body surface).
We studied patients in the former category (primary
hyperhidrosis at less common sites).
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Oxybutynin is an anti-muscarinic drug that was first
associated with the resolution of hyperhidrosis in 1988 (6).
Recently, specific therapy was reported (7,8) to be a good
initial alternative for treating primary hyperhidrosis; such
therapy has been used in plantar (9), axillary (10), palmar
(11,12) and facial hyperhidrosis (13) and has been evaluated
in a randomized, placebo-controlled trial (14). This therapy
is an alternative for patients who are not good surgical
candidates (either because of clinical limitations, such as age
or co-morbidities, or because of the applicability/efficacy of
sympathectomy in certain areas of the body).
Here, we report a case series of 20 patients with primary
focal hyperhidrosis whose main complaint was associated
with the less frequent sites of hyperhidrosis (e.g., the back or
groin) and who have been treated with the anticholinergic
oxybutynin for a median follow-up period of 385 days
(range: 133 – 1526 days).
& PATIENTS AND METHODS
This investigation was a non-randomized, uncontrolled
study; the data were retrospectively retrieved from our
dedicated and prospective institutional protocol, which is
standardized and has been in use at our facilities since 2001
for all patients with primary or compensatory hyperhidro-
sis.
From September 2007 to September 2013, 20 patients with
a primary complaint of focal hyperhidrosis at the dorsum
(n = 7), groin (n = 5), anterior thorax (n = 5), genitals (n = 1),
thighs (n = 1), and abdomen (n = 1) were included in our
pharmacological protocol using oxybutynin.
The inclusion criteria were as follows: patients with at
least two follow-up visits, patients who underwent an
extensive clinical investigation to exclude causes of second-
ary hyperhidrosis and patients with a detailed history of
previous drug use. The exclusion criteria were as follows:
contra indication to oxybutynin treatment (e.g., closed-angle
glaucoma or intestinal obstruction), report of night sweats
or climacterium and previous surgery involving the
sympathetic system (including oncologic or other proce-
dures in operative fields that could inadvertently include
the sympathetic ganglia, such as open aortic surgery).
The patient demographics are summarized in Table 1 and
a detailed description is provided in Table 2.
All subjects were treated following the same protocol.
During the first week, they received 2.5 mg of oxybutynin
once per day at bedtime. From days 8 to 21, they received
2.5 mg twice per day and from day 22 onward, they
received 5 mg twice per day. If necessary, the total dose was
increased up to 20 mg/day to balance the therapeutic and
side effects. Oxybutynin was provided by the hospital
pharmacy.
Three evaluations were performed for the purpose of this
study. The first occurred before medication was given, the
second occurred after six weeks of treatment and the final
evaluation occurred at least 24 weeks following the
initiation of the protocol (except for the patients who
stopped treatment earlier because of side effects). The
following information was evaluated: 1st) the patient’s
QOL was evaluated using a validated (and previously
employed (15)) questionnaire for patients with hyperhidro-
sis (3) before pharmacological treatment (Appendix 1); 2nd)
the patient’s clinical improvement at the main site of
hyperhidrosis was evaluated after six weeks; 3rd) the
patient’s QOL was evaluated after six weeks of oxybutynin
treatment (Appendix 1); 4th) the patients’ clinical improve-
ment at the main and other sites of hyperhidrosis was
evaluated at the final visit; and 5th) the patient’s complaints
of pharmacological side effects were evaluated after six
weeks and at the final visit.
Patients completed the clinical improvement question-
naire according to their subjective perception of the
improvement in sudoresis. They evaluated this improve-
ment using a scale ranging from 0 to 10, in which 0
represented no improvement and 10 represented the
absence of hyperhidrosis based on their own estimate. The
improvement was recorded as null when the score was 0,
slight when it was 1 to 4, moderate when it was 5 to 7 and
great when it was 8 to 10.
The negative impact of hyperhidrosis on the patient’s
QOL before oxybutynin was classified into five different
categories, calculated as the summed total score from the
protocol. When the total scores were.83, 68-83, 52-67, 36-51
and 20-35, the QOL was considered very poor, poor, good,
very good and excellent, respectively.
The QOL improvement after treatment was also classified
into five different categories. When the totals were greater
than 83, 68-83, 52-67, 36-51 and 20-35, the QOL was
considered much worse, slightly worse, the same, slightly
better and much better, respectively.
Statistical analysis
Means and standard deviations (SDs) were used in the
descriptive analysis of parametrically distributed continuous
variables, whereas frequencies were used for categorical
variables. McNemar’s test was used to compare self-reported
improvements in hyperhidrosis and dry mouth over time at
the two consecutive analysis time points.
The significance level for all tests was p= 0.05.
Ethics
This study was approved by the ethics committees of our
institutions, with the following protocol numbers: 374.680/
2013 at the Israelita Albert Einstein Hospital and 399.867/
Table 1 - Patient demographics.
%
Male n=10 50
Female n=10 50
Age at initiation of the protocol 17-72
Pre-pharmacological treatment quality of life (QOL)
Very poor N = 6 30
Poor n = 9 45
Good n = 5 25
Very good n = 0 0
Excellent n = 0 0
Total n = 20 100.0
QOL after six weeks of pharmacological treatment
Much worse 0 0
Worse n = 0 0
The same n = 3 15
Slightly better n = 4 20
Much better n = 13 65
Total n = 20 100.0
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2013 at Hospital das Clı´nicas. This study is registered at
Plataforma Brazil’s site as CAAE 01582112.6.1001.0071.
& RESULTS
There were ten males and ten females. All patients were
followed for at least four months. The median follow-up
period was 385 days (range: 133 – 1526 days).
The most bothersome sites for hyperhidrosis were the
back (Seven patients) followed by the groin (n = 5). Five
patients reported that they were more uncomfortable with
hyperhidrosis on the thorax. The second and third sites of
hyperhidrosis for each patient are displayed in Table 2.
QOL data before and six weeks after treatment are
presented in Table 1. Fifteen patients (75%) presented with
a poor or very poor QOL before pharmacological therapy
with oxybutynin. After six weeks, seventeen patients (85%)
reported some improvement in QOL.
The improvements in sweating at the main site after six
weeks and at the last visit are presented in Table 3. After six
weeks, 70% of the patients reported moderate/great
improvement in sweating, while 80% (16 out of 20) reported
moderate or great improvement in sweating at the last visit.
At the second most disturbing site of hyperhidrosis, 88.9%
(16 out of 18) of the cases showed moderate or great
improvement.
Comparing the improvement at the six-week analysis
with the last evaluation (Table 3), 45% of patients remained
in the same category of improvement, 15% ‘‘downgraded’’
and 40% improved over the course of the study. The change
in sub-categories was not statistically significant
(McNemar’s test: p= 0.139).
Regarding side effects, no patients reported intestinal
obstruction, urinary retention, or decreased visual acuity.
Dry mouth was the most common complaint, as only four
patients (20%) did not report some degree of dry mouth.
Twelve subjects rated dry mouth as moderate/severe and
two of these subjects stopped treatment because of this
complaint. Two patients reported somnolence (which made
both of them cease treatment), and one case of alleged heart
palpitation/tachycardia was noted (the patient was not
thoroughly investigated because she decided to stop the
medication and did not want to try it again). In total, five
patients ceased taking the medication.
Comparisons of dry mouth complaints after six weeks
and at the last visit are shown in Table 4; 85% of the patients
remained in the same category (absent/light or moderate/
severe) throughout the study period and 15% reported
Table 3 - Improvement at the main site of hyperhidrosis after six weeks and at the last consult (median: 385 days).
Improvement at the main site of compensatory hyperhidrosis at the
last consult Total McNemar’s p
Null
Slight
improvement
Moderate
improvement Great improvement
Improvement at
the main site of
compensatory
hyperhidrosis
after six weeks
Null Count 0 0 0 1 1 0.139
% 0.0% 0.0% 0.0% 100.0% 100.0%
Slight improvement Count 0 1 2 2 5
% 0.0% 20.0% 40.0% 40.0% 100.0%
Moderate
improvement
Count 2 0 3 3 8
% 25.0% 0.0% 37.5% 37.5% 100.0%
Great improvement Count 0 1 0 5 6
% 0.0% 16.7% 0.0% 83.3% 100.0%
Total Count 2 2 5 11 20
% 10.0% 10.0% 25.0% 55.0% 100.0%
Consistency: 45%; Improvement: 40%; Worsening: 15%.
Table 4 - Comparison of dry mouth complaints after six weeks and at the last consult.
Dry mouth complaint at the last visit Total McNemar’s p
Absent/Mild Moderate/Intense
Dry mouth
complaint
after six
weeks of
treatment
Absent/Mild Count 5 0 5 0.250
% 100.0% 0.0% 100.0%
Moderate/Intense Count 3 12 15
% 20.0% 80.0% 100.0%
Total Count 8 12 20
% 40.0% 60.0% 100.0%
Consistency: 85%; Improvement: 0%; Worsening: 15%.
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worsening of this symptom. The change in the sub-
categories was not statistically significant (McNemar’s test:
p= 0.250).
& DISCUSSION
It is estimated that there are up to 600-700 sweat glands/
cm2 on the palms and soles, 350/cm2 on the forehead,
64/cm2 on the back and 60/cm2 on the thigh (16-18). This
estimation correlates with epidemiological findings that
palmar and plantar (along with axillary) hyperhidrosis are
among the most common presentations (19).
Our service treats primary hyperhidrosis in a large
number of patients. When we classify patients by their
primary site complaint, we observe the following approx-
imate figures: 500 patients with palmar, 400 with axillary,
100 with cranio-facial and 75 with plantar hyperhidrosis. In
our service, we estimate that the incidence of primary
sweating at uncommon sites is approximately 1.85%, which
might be the reason for underreporting in the literature.
Maillard et al. (20) coined the term ‘‘primary extensive
hyperhidrosis’’ for patients with at least three sites of
excessive sweating, including both ‘‘typical’’ (hands and
feet) and ‘‘unusual’’ sites (trunk and groin); however, the
association of the primary complaint with ‘‘unusual’’ sites is
not critical to their definition.
Focal primary hyperhidrosis at common sites (hands,
armpits, feet and face) has been extensively studied, and
different methods of treatment have been described (21),
including topical therapy (22) (iontophoresis, botulin toxin
and aluminum compounds), surgery (either excision of
sweat glands in axillary hyperhidrosis (23), thoracic
sympathectomy for upper limb/face sweating (24) or
lumbar sympathectomy for plantar sudoresis (25)) and
pharmacological therapy with anticholinergics, such as
oxybutynin (12), glycopyrrolate and clonidine (26).
Widespread sudoresis – also referred to as generalized
hyperhidrosis, a condition that has not been precisely
defined – is usually considered to be a secondary effect
that is associated with drug side effects (or drug with-
drawal) or with clinical conditions (e.g., menopause,
pheochromocytoma, carcinoid syndrome, thyrotoxicosis,
or diabetes mellitus) (18,27).
Primary focal sweating in uncommon sites, on the other
hand, does not share the same profile. Local therapies (e.g.,
iontophoresis or aluminum compounds) do not have great
applicability; botulin toxin may harbor a significant risk, as
there have been case reports of clinical botulism after
treatment for axillary and palmar hyperhidrosis (28).
Additionally, the likelihood of contracting botulism is
theoretically increased if a larger (e.g., abdominal) area is
treated. Removal of sweat glands, which may be done in
axillary hyperhidrosis, is not readily achievable at many
other sites. Surgical sympathectomy is not considered
routine for unusual sites and may aggravate hyperhidrosis
in other locations (as observed with compensatory hyperhi-
drosis).
Nevertheless, our results indicate that this illness con-
siderably affects QOL (75% presented poor/very poor QOL
before treatment). This result is comparable to most studies
that have assessed the impact of hyperhidrosis on QOL.
Oral systemic therapy appears to be an ideal solution for
complaints that are not amenable to local/surgical therapy.
Our group decided to study the effect of oxybutynin in
clinical scenarios in which patients presented with a poor
QOL due to excessive sweating. Our cohort presented an
85% improvement in QOL (using the Milanez de Campos
scale, which has been used by other authors (15) for this
purpose); these findings are similar to those achieved with
certain treatments at typical sites, after which the QOL is
usually greatly enhanced (3,11,29,30).
The QOL significantly improved after six weeks of
treatment, which is similar to the improvement observed
after the use of oxybutynin for common sites.
To evaluate the improvement in sweating, we relied on
patient self-assessment, although objective measures are
technically feasible with sudorometers (31) or with the
Minor test (i.e., the starch-iodine test, in which a 2% iodine
solution is applied to the hyperhidrotic area and allowed to
dry; next, starch in powder form is subsequently applied to
the area and the transformation from brown to dark purple
demonstrates the area of sweating, which can be photo-
graphed and compared during follow-up visits). These
results are available only at a specific time point instead of
throughout the day. Hyperhidrosis is a bothersome – but
not lethal – condition and the goal of treatment is the
subjective amelioration of symptoms; thus, patient self-
reporting is an adequate method for data collection.
When we compare the self-improvement after six weeks
with the results of the last visit (Table 3) after a median of
385 days, only 15% of patients ‘‘downgraded’’ their
evaluation, which means that after one year, most patients
tended to maintain a pharmacological response to hyperhi-
drosis. Gender did not appear to affect the outcomes, as the
proportion of good responses did not differ between males
and females. This finding is comparable to the outcomes
after sympathectomy for palmar hyperhidrosis (32), in
which the improvement was unrelated to gender.
Unfortunately, systemic therapy has its drawbacks: dry
mouth was the most common side effect (12 patients
reported moderate/severe dry mouth at the last visit) and
led to two withdrawals from treatment. This dry mouth,
although not statistically significant (McNemar’s p= 0.25),
tended to become worse in 15% of patients by the last visit
when compared to the six-week follow up visit.
Other significant side effects that led to cessation of
treatment were somnolence, which heavily interfered with
daily activities in two patients and one complaint of
palpitations and tachycardia associated with the medica-
tion. Although transient tachycardia has been reported in a
case of oxybutynin poisoning at a dose of 100 mg (33), this is
not a typical finding; other diagnoses should have been
investigated, but the patient decided to stop the medication
and never take it again.
Anticholinergics have been successfully used in compen-
satory hyperhidrosis (15), which has a different pathophy-
siological mechanism with a clinical presentation that is
similar to that observed in our patients with primary
hyperhidrosis at uncommon sites. Our study indicates that
oxybutynin yields significant improvement in both self-
perceived sweating and QOL in these patients, with a
reasonably tolerable side effect profile. Additionally, this
improvement is maintained over the long term.
Our retrospective analysis indicates that, even for patients
who presented with hyperhidrosis at uncommon sites, there
was a generally good response to oxybutynin and these
results were longstanding. Obviously, such treatment must
be performed only after extensive investigation to rule out
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secondary hyperhidrosis, which may be less common, but
potentially more dangerous (e.g: pheocromocytomas, and B
symptons associated with lymphomas).
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